Ernexa Therapeutics prices $10.5M stock offering

Got story updates? Submit your updates here. ›

Ernexa Therapeutics Inc., an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, announced the pricing of a best-efforts registered public offering of 21,000,000 shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to 21,000,000 shares of common stock, at a combined public offering price of $0.50 per share (or per common stock equivalent in lieu thereof) and accompanying warrant.

Why it matters

The proceeds from this offering will allow Ernexa to advance its development programs, including its lead cell therapy product ERNA-101 designed to activate and regulate the immune system's response to recognize and attack cancer cells, as well as ERNA-201 for targeting inflammation and treating autoimmune disease.

The details

The warrants will have an exercise price of $0.68 per share, will be exercisable upon issuance, and will expire on the earlier to occur of (i) the five-year anniversary of the initial issuance date, or (ii) the 180th calendar day following the public release by the Company of clinical trial data from the first cohort of the Phase 1 study of ERNA-101. The closing of the offering is expected to occur on or about February 10, 2026, subject to the satisfaction of customary closing conditions. Brookline Capital Markets, a division of Arcadia Securities, LLC is acting as the exclusive placement agent for the offering.

• The offering is expected to close on or about February 10, 2026.
• The warrants will expire on the earlier of the five-year anniversary of the issuance date or 180 days after the public release of Phase 1 data for ERNA-101.

What’s next

The closing of the offering is expected to occur on or about February 10, 2026, subject to the satisfaction of customary closing conditions.